Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 250 of 494 entries
View as:

Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS

Phase: N/A Priority: Normal
NCT ID: NCT00884481 Org: User:
Start: 03/23/09 End: 06/30/11 Due: 06/30/12

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00493077 Org: User:
Start: 05/31/04 End: 05/31/06 Due: 05/31/07

A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05119790 Org: User:
Start: 08/27/21 End: 11/05/21 Due: 11/05/22

PK and PD Study of Natalizumab in Pediatric Subjects With RRMS

Phase: N/A Priority: Normal
NCT ID: NCT01884935 Org: User:
Start: 07/31/13 End: 09/30/14 Due: 09/30/15

Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients

Phase: N/A Priority: Normal
NCT ID: NCT00784836 Org: User:
Start: 10/31/08 End: 02/28/09 Due: 02/28/10

A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)

Phase: N/A Priority: Normal
NCT ID: NCT03864614 Org: User:
Start: 02/27/19 End: 06/22/23 Due: 06/22/24

Open-Label Natalizumab Safety Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT00276172 Org: User:
Start: 12/31/03 End: 01/31/06 Due: 01/31/07

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02294851 Org: User:
Start: 12/31/14 End: 04/30/16 Due: 04/30/17

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00599274 Org: User:
Start: 08/31/02 End: 05/31/03 Due: 05/31/04

A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01215084 Org: User:
Start: 10/31/10 End: 11/30/10 Due: 11/30/11

Systemic Sclerosis Clinical and Biomarker Study

Phase: N/A Priority: Normal
NCT ID: NCT02531009 Org: User:
Start: 12/31/15 End: 03/31/17 Due: 03/31/18

Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes

Phase: N/A Priority: Normal
NCT ID: NCT02833142 Org: User:
Start: 07/31/16 End: 11/30/16 Due: 11/30/17

A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS

Phase: N/A Priority: Normal
NCT ID: NCT00837785 Org: User:
Start: 02/28/09 End: 10/31/09 Due: 10/31/10

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy

Phase: N/A Priority: Normal
NCT ID: NCT02193074 Org: User:
Start: 08/19/14 End: 11/21/16 Due: 11/21/17

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01416181 Org: User:
Start: 09/13/11 End: 04/13/16 Due: 04/13/17

Exploring Diroximel Fumarate Real-world Experience in Canada and Israel

Phase: N/A Priority: Normal
NCT ID: NCT04948606 Org: User:
Start: 12/09/21 End: 04/14/23 Due: 04/14/24

A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06264440 Org: User:
Start: 02/12/24 End: 06/18/24 Due: 06/18/25

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05195008 Org: User:
Start: 01/24/22 End: 07/10/23 Due: 07/10/24

A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01749098 Org: User:
Start: 12/31/12 End: 02/28/14 Due: 02/28/15

A Study to Learn About the Safety of Salanersen (BIIB115) Injections and How Salanersen is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec

Phase: N/A Priority: Normal
NCT ID: NCT05575011 Org: User:
Start: 10/10/22 End: 11/19/26 Due: 11/19/27

Avonex 15 Year Long Term Follow-up Study

Phase: N/A Priority: Normal
NCT ID: NCT00525343 Org: User:
Start: 03/31/07 End: 09/30/08 Due: 09/30/09

A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model

Phase: N/A Priority: Normal
NCT ID: NCT03284931 Org: User:
Start: 09/14/17 End: 12/18/17 Due: 12/18/18

Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection

Phase: N/A Priority: Normal
NCT ID: NCT04419233 Org: User:
Start: 11/18/20 End: 11/21/23 Due: 11/21/24

Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00102024 Org: User:
Start: 01/31/05 End: 01/31/06 Due: 01/31/07

Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT02219932 Org: User:
Start: 09/30/14 End: 02/29/16 Due: 02/28/17